Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | CCR1 | P32246 | 8/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2287326 | 0.91 | GFER (0.47) | GFERCCR1MEN1KMT2AADRB1 | |
| SCHEMBL904589 | 0.90 | MEN1 (0.54) | GFERHTTMEN1KMT2A | |
| SCHEMBL12378451 | 0.90 | ADRB1 (0.55) | GFERHTTNPSR1MEN1KMT2A | |
| SCHEMBL904556 | 0.90 | ADRB1 (0.55) | GFERHTTNPSR1MEN1KMT2A | |
| SCHEMBL12378435 | 0.90 | ADRB1 (0.55) | GFERHTTNPSR1MEN1KMT2A | |
| SCHEMBL2293764 | 0.87 | MAPT (0.47) | POLBGFERCCR1HTTMEN1 | |
| SCHEMBL904633 | 0.87 | KMT2A (0.60) | POLBHTTMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL904428 | 0.87 | MAPT (0.46) | POLBGFERCCR1HTTMEN1 | |
| SCHEMBL2291221 | 0.84 | TDP1 (0.55) | GFERMEN1KMT2AADRB1HTR2A | |
| SCHEMBL2288329 | 0.83 | ADRB1 (0.52) | HTTNPSR1MEN1KMT2AADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238633-B2 | Methods for treating diabetic complications with carbamoyloxy arylalkanoyl arylpiperazine compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-01-19 | — | — | US | claimed |
| US-8901116-B2 | Method for treating pain, anxiety or depression using carbamoyloxy alkanoyl piperazine compound | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-12-02 | — | — | US | claimed |
| US-20140243352-A1 | METHODS FOR TREATING DIABETIC COMPLICATIONS WITH CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-08-28 | — | — | US | claimed |
| US-20140088095-A1 | METHOD FOR TREATING PAIN, ANXIETY OR DEPRESSION USING CARBAMOYLOXY ALKANOYL PIPERAZINE COMPOUND | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-03-27 | — | — | US | claimed |
| US-8648083-B2 | Method of treating diabetic hyperlipidemia or hyperlipidemia with carbamoyloxy arylalkanoyl arylpiperazine compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-02-11 | — | — | US | claimed |
| US-8541409-B2 | Carbamoyloxy arylalkanoyl arylpiperazine analgesics | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-09-24 | — | — | US | claimed |
| US-20130131081-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-05-23 | — | — | US | claimed |
| EP-2590650-A2 | PHARMACEUTICAL COMPOSITIONS INCLUDING CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND | SK Biopharmaceuticals Co., Ltd. (KR) | 2013-05-15 | — | — | EP | claimed |
| WO-2012005536-A2 | PHARMACEUTICAL COMPOSITIONS INCLUDING CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2012-01-12 | — | — | WO | claimed |
| US-9238633-B2 | Methods for treating diabetic complications with carbamoyloxy arylalkanoyl arylpiperazine compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-01-19 | — | — | US | disclosed |
| US-9238633-B2 | Methods for treating diabetic complications with carbamoyloxy arylalkanoyl arylpiperazine compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-01-19 | — | — | US | disclosed |
| US-9238633-B2 | Methods for treating diabetic complications with carbamoyloxy arylalkanoyl arylpiperazine compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-01-19 | — | — | US | disclosed |
| US-8901116-B2 | Method for treating pain, anxiety or depression using carbamoyloxy alkanoyl piperazine compound | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-12-02 | — | — | US | disclosed |
| US-8901116-B2 | Method for treating pain, anxiety or depression using carbamoyloxy alkanoyl piperazine compound | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-12-02 | — | — | US | disclosed |
| US-20110195963-A1 | NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2011-08-11 | — | — | US | disclosed |
| US-20110195963-A1 | NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2011-08-11 | — | — | US | disclosed |
| US-20110195963-A1 | NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2011-08-11 | — | — | US | disclosed |
| US-20100160331-A1 | NOVEL CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK HOLDINGS CO. LTD. (KR) | 2010-06-24 | — | — | US | disclosed |
| US-20100160331-A1 | NOVEL CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK HOLDINGS CO. LTD. (KR) | 2010-06-24 | — | — | US | disclosed |
| US-20100160331-A1 | NOVEL CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK HOLDINGS CO. LTD. (KR) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160331-A1 | NOVEL CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | HTR5A, OPRD1, OPRL1 | POLB 4673/4885GFER 4454/4885CCR1 897/4885 |
| US-20130131081-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND | LIPG, CETP, GPR119 | POLB 4519/4885GFER 1619/4885CCR1 542/4885 |
| US-20110195963-A1 | NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | HTR5A, CNR2, CNR1 | POLB 4701/4885GFER 4413/4885CCR1 1098/4885 |
| US-20140088095-A1 | METHOD FOR TREATING PAIN, ANXIETY OR DEPRESSION USING CARBAMOYLOXY ALKANOYL PIPERAZINE COMPOUND | HTR5A, OPRL1, HDAC3 | POLB 4080/4885GFER 4264/4885CCR1 1266/4885 |
| US-20140243352-A1 | METHODS FOR TREATING DIABETIC COMPLICATIONS WITH CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUNDS | LIPG, DPP7, IAPP | POLB 4017/4885GFER 1531/4885CCR1 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.